Company intelligence / Profile preview
Biomed Industries, Inc.
Kansas City, Missouri, United Statesbiomedcentral.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Multiple products in clinical development with NA-831 ready for Phase 3 trials for Alzheimer's Disease, NA-901 ready for Phase 2/3 for Major Depressive Disorder, NA-931 (Bioglutide™) for obesity, NA-704 in Phase 2A for ALS and Parkinson's, and NA-921 (Bionetide™) in Phase 3 for Rett Syndrome. The MICROS controlled release infusion system has been approved for marketing in the US.
- Therapeutic areas
- PsychiatryGastroenterologyNeurologyEndocrinology
- Modalities
- Small moleculesEnzyme substitution therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Request access →03
Partnerships
MedAware Systems, Inc.
Beyond the preview
Go deeper on Biomed Industries, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biomed Industries, Inc..